| scholarly article | Q13442814 |
| P50 | author | William G Wierda | Q64026278 |
| P2093 | author name string | Philip A Thompson | |
| P2860 | cites work | Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia | Q24681296 |
| Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia | Q28140129 | ||
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. | Q31099184 | ||
| Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33402713 | ||
| Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia | Q33410917 | ||
| Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 | ||
| Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. | Q33794311 | ||
| Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion | Q33978930 | ||
| Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia | Q34009041 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
| Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 | ||
| Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. | Q51741519 | ||
| A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia. | Q51840035 | ||
| International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. | Q52854227 | ||
| Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies. | Q54579547 | ||
| Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. | Q54620000 | ||
| Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | Q56657194 | ||
| Evaluation of Residual Disease in B-Cell Chronic Lymphocytic Leukemia Patients in Clinical and Bone-Marrow Remission Using CD5-CD19 Markers and PCR Study of Gene Rearrangements | Q58416433 | ||
| Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis | Q67897527 | ||
| Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value | Q72528752 | ||
| A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors | Q73767400 | ||
| Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry | Q73879747 | ||
| Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group ( | Q82903582 | ||
| Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial | Q83441006 | ||
| Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis | Q84314482 | ||
| Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase | Q84513629 | ||
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
| Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia | Q34402999 | ||
| Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia. | Q35040222 | ||
| Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. | Q35134983 | ||
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
| Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) | Q35694453 | ||
| Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. | Q35723986 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer | Q36177909 | ||
| Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia | Q36509641 | ||
| Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia | Q36597026 | ||
| Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens | Q37028643 | ||
| Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. | Q37087424 | ||
| Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses | Q37104775 | ||
| Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation | Q37175581 | ||
| Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia | Q37634897 | ||
| Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial | Q38001693 | ||
| Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy. | Q38010503 | ||
| The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time? | Q38096536 | ||
| Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers | Q38169637 | ||
| Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial | Q38424831 | ||
| The leukaemic phase of non-Hodgkin's lymphoma | Q39643605 | ||
| Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy | Q40701090 | ||
| A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia | Q40887155 | ||
| Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug | Q42547378 | ||
| Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial | Q42994283 | ||
| Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). | Q43412767 | ||
| Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). | Q43430617 | ||
| Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. | Q44539030 | ||
| Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. | Q44892386 | ||
| Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). | Q45046700 | ||
| Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. | Q45110231 | ||
| Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival | Q45287934 | ||
| IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide | Q46064600 | ||
| Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia | Q46378902 | ||
| Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication | Q46825515 | ||
| Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia | Q46913558 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 279-286 | |
| P577 | publication date | 2015-11-17 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. | |
| P478 | volume | 127 |
| Q93031655 | A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia |
| Q45051052 | A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma |
| Q99628496 | BTK Inhibitors and Chemoimmunotherapy for CLL |
| Q89475666 | CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression |
| Q50121608 | Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. |
| Q48152651 | Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group. |
| Q56270980 | Chronic lymphocytic leukaemia |
| Q40126133 | Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib |
| Q38905607 | Clinical Trials in the Genomic Era. |
| Q38789282 | Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials |
| Q37429218 | Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. |
| Q61755942 | Diagnostic Applications of Nuclear Medicine: Leukemias |
| Q91774709 | Dual-action CXCR4-targeting liposomes in leukemia: function blocking and drug delivery |
| Q48762439 | Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000. |
| Q54108755 | Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. |
| Q38671671 | Evolution of lymphoma staging and response evaluation: current limitations and future directions |
| Q92715263 | Frontline therapies for untreated chronic lymphoid leukemia |
| Q37097867 | HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment |
| Q92487708 | High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance |
| Q38672646 | High-throughput sequencing for noninvasive disease detection in hematologic malignancies. |
| Q37528067 | Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. |
| Q92823144 | Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial |
| Q98199298 | Integrated mechanistic model of minimal residual disease kinetics with venetoclax therapy in chronic lymphocytic leukemia |
| Q47905658 | Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Q55644886 | Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia. |
| Q39420524 | Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil |
| Q37508066 | Measure for measure: minimal residual disease in CLL. |
| Q92671839 | Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine? |
| Q90292627 | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? |
| Q52801615 | Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. |
| Q47873950 | Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions |
| Q90181898 | Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy |
| Q88636732 | Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study |
| Q47582687 | Optimizing frontline therapy of CLL based on clinical and biological factors. |
| Q91842078 | Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL |
| Q91597257 | Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples |
| Q53963822 | Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. |
| Q38818283 | Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. |
| Q52690102 | Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. |
| Q61804713 | Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab |
| Q99551365 | Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia |
| Q52812536 | Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward? |
| Q38862525 | Recent advances in therapy of chronic lymphocytic leukaemia |
| Q46318389 | Recent therapeutic advances in chronic lymphocytic leukemia |
| Q39635163 | Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. |
| Q88701299 | Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies |
| Q42777547 | Single cell analysis of normal and leukemic hematopoiesis |
| Q91012563 | Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation |
| Q90047057 | Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer |
| Q89493561 | The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma |
| Q38719429 | The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia |
| Q57471770 | Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Q52770382 | Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia. |
Search more.